ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 182 filers reported holding ASCENDIS PHARMA A/S in Q1 2022. The put-call ratio across all filers is 0.64 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $0 | – | 0 | – | 0.00% | – |
| Q2 2023 | $0 | – | 0 | – | 0.00% | – |
| Q1 2023 | $0 | – | 0 | – | 0.00% | – |
| Q4 2022 | $0 | – | 0 | – | 0.00% | – |
| Q3 2022 | $0 | – | 0 | – | 0.00% | – |
| Q2 2022 | $0 | – | 0 | – | 0.00% | – |
| Q1 2022 | $0 | -100.0% | 0 | -100.0% | 0.00% | – |
| Q4 2021 | $1,000 | -98.3% | 7 | -98.1% | 0.00% | -100.0% |
| Q3 2021 | $59,000 | +5.4% | 371 | -13.5% | 0.00% | 0.0% |
| Q2 2021 | $56,000 | +3.7% | 429 | +2.9% | 0.00% | 0.0% |
| Q1 2021 | $54,000 | -6.9% | 417 | +20.9% | 0.00% | 0.0% |
| Q4 2020 | $58,000 | +34.9% | 345 | +23.2% | 0.00% | 0.0% |
| Q3 2020 | $43,000 | +72.0% | 280 | +67.7% | 0.00% | +100.0% |
| Q2 2020 | $25,000 | – | 167 | – | 0.00% | – |
| Q1 2020 | $0 | – | 0 | – | 0.00% | – |
| Q4 2019 | $0 | – | 0 | – | 0.00% | – |
| Q3 2019 | $0 | – | 0 | – | 0.00% | – |
| Q2 2019 | $0 | – | 0 | – | 0.00% | – |
| Q1 2019 | $0 | – | 0 | – | 0.00% | – |
| Q4 2018 | $0 | – | 0 | – | 0.00% | – |
| Q3 2018 | $0 | – | 0 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 11,225,357 | $1,001,863,112 | 18.92% |
| Q Global Advisors, LLC | 195,000 | $17,404 | 12.55% |
| Sofinnova Investments, Inc. | 754,032 | $67,297,356 | 4.41% |
| Avoro Capital Advisors LLC | 3,580,555 | $319,564,534 | 4.34% |
| Finepoint Capital LP | 139,772 | $12,474,651 | 4.32% |
| Spyglass Capital Management LLC | 657,853 | $58,713,380 | 4.24% |
| Saturn V Capital Management LP | 78,442 | $7,000,948 | 3.88% |
| DAFNA Capital Management LLC | 135,212 | $12,067,671 | 3.30% |
| ARS Investment Partners, LLC | 289,860 | $25,870,005 | 3.02% |
| Ghost Tree Capital, LLC | 100,000 | $8,925,000 | 2.95% |